Counterfeit Cancer Drugs Flooding Market: Delhi Police Arrest 4 in ₹10 Crore Scam

Date:

Share post:

In a major crackdown on pharmaceutical fraud, the Delhi Police Crime Branch has dismantled an alleged counterfeit drug syndicate involved in the manufacturing and distribution of fake medicines worth nearly ₹10 crore. Four individuals have been arrested in connection with the operation, which reportedly supplied counterfeit drugs used for the treatment of cancer, liver disorders, hepatitis, diabetes, and other serious health conditions.

During raids conducted in Delhi, officials seized thousands of fake capsules and tablets, packaging materials, labels, and machinery allegedly used to replicate branded medicines. Preliminary investigations suggest the network operated across multiple states, raising concerns over the growing circulation of counterfeit medicines within the healthcare supply chain.

Authorities are also probing possible links to illegal diversion of genuine medicines and financial irregularities connected to the racket. The incident has once again highlighted the urgent need for stronger regulatory oversight and stricter monitoring to safeguard patient safety and public health.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Dabur India Plant Under US FDA Scanner Over Contamination Concerns

The United States Food and Drug Administration (US FDA) has flagged serious concerns at Dabur India's manufacturing facility...

FDA Approves Wockhardt’s Novel Antibiotic ZAYNICH™️ for cUTI

Wockhardt Limited  announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepimeand zidebactam), a novel intravenous antibiotic...

Relief for Patients: NPPA Fixes Ceiling Prices for 30 Essential Medicines

The National Pharmaceutical Pricing Authority (NPPA) has notified ceiling prices for 30 essential fixed-dose combination medicines under the...

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The U.S. Food and Drug Administration (FDA) issued a new draft guidance aimed at reducing unnecessary animal testing...